$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000115903614000093 Filed on November 10, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$30.38M	$14.61M	$12.50M
YoY Change	143.04%	-8.79%	-42.65%
Cost Of Revenue	$6.100M	$5.141M	$3.500M
YoY Change	74.29%	652.71%	400.0%
Gross Profit	$3.997M	$4.476M	$6.266M
YoY Change	-36.21%	-52.09%	677.56%
Gross Profit Margin	13.16%	30.64%	50.13%
Selling, General & Admin	$8.400M	$8.587M	$9.400M
YoY Change	-10.64%	5.56%	34.29%
% of Gross Profit	210.16%	191.85%	150.02%
Research & Development	$19.70M	$19.90M	$20.90M
YoY Change	-5.74%	-22.52%	12.37%
% of Gross Profit	492.87%	444.68%	333.55%
Depreciation & Amortization	$500.0K	$500.0K	$300.0K
YoY Change	66.67%	66.67%	0.0%
% of Gross Profit	12.51%	11.17%	4.79%
Operating Expenses	$28.10M	$28.49M	$30.30M
YoY Change	-7.26%	-15.77%	18.82%
Operating Profit	-$24.10M	-$19.03M	-$24.03M
YoY Change	0.29%	2.88%	-2.67%
Interest Expense	-$1.400M	$1.376M	-$700.0K
YoY Change	100.0%	61.88%
% of Operating Profit
Other Income/Expense, Net		$122.0K
YoY Change		134.62%
Pretax Income	-$5.300M	-$20.30M	-$22.00M
YoY Change	-75.91%	5.18%	400.0%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.274M	-$20.28M	-$21.99M
YoY Change	-76.01%	5.12%	399.02%
Net Earnings / Revenue	-17.36%	-138.85%	-175.9%
Basic Earnings Per Share		-$0.16
Diluted Earnings Per Share	-$42.64K	-$163.7K	-$193.7K
COMMON SHARES
Basic Shares Outstanding	125.4M shares	124.0M shares	114.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$135.6M	$134.5M	$71.50M
YoY Change	89.65%	105.97%	-28.14%
Cash & Equivalents	$61.39M	$46.38M	$27.36M
Short-Term Investments	$74.20M	$88.10M	$44.10M
Other Short-Term Assets	$10.10M	$8.900M	$8.400M
YoY Change	20.24%	-2.2%	-34.38%
Inventory	$6.406M	$6.916M	$6.170M
Prepaid Expenses
Receivables	$9.149M	$8.275M	$9.097M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$161.3M	$158.6M	$95.20M
YoY Change	69.46%	54.25%	-27.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.951M	$3.249M	$3.422M
YoY Change	-13.76%	-34.18%	-7.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$2.800M	$3.200M
YoY Change	-46.88%	16.67%	700.0%
Total Long-Term Assets	$4.656M	$6.026M	$6.598M
YoY Change	-29.43%	-17.76%	60.91%
TOTAL ASSETS
Total Short-Term Assets	$161.3M	$158.6M	$95.20M
Total Long-Term Assets	$4.656M	$6.026M	$6.598M
Total Assets	$166.0M	$164.6M	$101.8M
YoY Change	63.05%	49.46%	-24.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.003M	$4.342M	$3.135M
YoY Change	-4.21%	-22.35%	38.0%
Accrued Expenses	$13.96M	$15.02M	$14.37M
YoY Change	-2.84%	-27.16%	84.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$10.08M	$0.00
YoY Change		68.76%
Total Short-Term Liabilities	$24.33M	$34.59M	$24.90M
YoY Change	-2.29%	-12.7%	31.44%
LONG-TERM LIABILITIES
Long-Term Debt	$49.86M	$39.80M	$49.77M
YoY Change	0.18%	51.33%	67.8%
Other Long-Term Liabilities	$3.167M	$2.759M	$1.364M
YoY Change	132.18%	199.42%
Total Long-Term Liabilities	$53.03M	$2.759M	$51.14M
YoY Change	3.7%	199.42%	72.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.33M	$34.59M	$24.90M
Total Long-Term Liabilities	$53.03M	$2.759M	$51.14M
Total Liabilities	$77.36M	$37.35M	$76.04M
YoY Change	1.74%	-7.88%	56.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$450.4M	-$445.2M	-$382.1M
YoY Change	17.9%	23.63%	27.96%
Common Stock	$491.8M	$485.1M	$362.0M
YoY Change	35.84%	36.06%	4.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.35M	$39.94M	-$19.99M
YoY Change
Total Liabilities & Shareholders Equity	$166.0M	$164.6M	$101.8M
YoY Change	63.05%	49.46%	-24.45%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$5.274M	-$20.28M	-$21.99M
YoY Change	-76.01%	5.12%	399.02%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$300.0K
YoY Change	66.67%	66.67%	0.0%
Cash From Operating Activities	-$900.0K	-$13.20M	-$15.20M
YoY Change	-94.08%	6.45%	-10.06%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$300.0K	-$1.400M
YoY Change	-78.57%	0.0%	180.0%
Acquisitions
YoY Change
Other Investing Activities	$13.70M	$3.000M	$3.300M
YoY Change	315.15%
Cash From Investing Activities	$13.40M	$2.700M	$2.000M
YoY Change	570.0%	-1000.0%	-500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.500M	800.0K	23.10M
YoY Change	-89.18%	-65.22%	-22.22%
NET CHANGE
Cash From Operating Activities	-900.0K	-13.20M	-15.20M
Cash From Investing Activities	13.40M	2.700M	2.000M
Cash From Financing Activities	2.500M	800.0K	23.10M
Net Change In Cash	15.00M	-9.700M	9.900M
YoY Change	51.52%	-6.73%	-19.51%
FREE CASH FLOW
Cash From Operating Activities	-$900.0K	-$13.20M	-$15.20M
Capital Expenditures	-$300.0K	-$300.0K	-$1.400M
Free Cash Flow	-$600.0K	-$12.90M	-$13.80M
YoY Change	-95.65%	6.61%	-15.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7140000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4176000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3135000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4342000	USD
CY2014Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9147000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11065000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9707000	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8275000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9097000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1062000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-816000	USD
CY2013Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14920000	USD
CY2014Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15446000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14369000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15023000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8856000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7649000	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-46000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361930000	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	485014000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2304000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1037000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1610000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8600000	shares
CY2013Q4	us-gaap	Assets Assets	101793000	USD
CY2014Q3	us-gaap	Assets Assets	164626000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	95195000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	158600000	USD
CY2013Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	49856000	USD
CY2014Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	127000000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44146000	USD
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	88089000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44129000	USD
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	88135000	USD
CY2014Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	88089000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	44146000	USD
CY2014Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	9100000	USD
CY2014Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	79000000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	20000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	11000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	3000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	57000	USD
CY2014Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	13
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46375000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17492000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19018000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-82009000	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114533000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125546000	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125546000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114533000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	115000	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	125000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61476000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63164000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19237000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20329000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5141000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16585000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2706000	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	683000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	104142000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	101411000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	34507000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	33632000	USD
	us-gaap	Debt Instrument Covenant Compliance DebtInstrumentCovenantCompliance	Yes
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	53143000	USD
CY2014Q3	us-gaap	Deferred Revenue DeferredRevenue	52725000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5153000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7398000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45745000	USD
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	47572000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	900000	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	USD
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1304000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	893000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4555000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7075000	USD
CY2014Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16071000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1693000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8819000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-822000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-418000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9532000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	746000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1176000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-39000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	32000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-98000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2018000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000	USD
	us-gaap	Interest Expense InterestExpense	2547000	USD
	us-gaap	Interest Expense InterestExpense	4203000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	1376000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	850000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2500000	USD
CY2013Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	900000	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1400000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	4200000	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1965000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	753000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	6170000	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	6916000	USD
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1252000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1137000	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	3699000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4280000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101793000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164626000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	34593000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24902000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	27667000	USD
CY2013Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	5988000	USD
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2094000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	11896000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	49772000	USD
CY2014Q3	us-gaap	Long Term Debt LongTermDebt	39762000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	10075000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as oncology, diabetes and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid, a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We have one proprietary commercial product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant, which we market ourselves, used to increase the dispersion and absorption of other injected drugs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists of multiple clinical stage product candidates in oncology, diabetes and dermatology. Our lead oncology program is PEGPH20, a new molecular entity, under development for the systemic treatment of tumors that accumulate hyaluronic acid. We are currently in Phase 2 clinical testing for PEGPH20 in pancreatic cancer. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Pfizer Inc. (“Pfizer”) and Baxter Healthcare Corporation (“Baxter”), with one product approved in the U.S. and three products approved in Europe from which we are receiving royalties and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Condensed Consolidated Financial Statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.'s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1996000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	112030000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49886000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46433000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46579000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34119000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-19292000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-63101000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-20280000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-61492000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59185000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18494000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19026000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59110000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1235000	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1849000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	18000	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1500000	USD
CY2013Q4	us-gaap	Other Assets OtherAssets	356000	USD
CY2014Q3	us-gaap	Other Assets OtherAssets	381000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-63000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-49000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	55000	USD
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2759000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1364000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	122000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	287000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	165000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52000	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1339000	USD
CY2014Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1654000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	89117000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48947000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1132000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	939000	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11101000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11222000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8945000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8425000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2277000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2676000	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2014Q3	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1996000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4317000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43816000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12105000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11071000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3422000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3249000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19904000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25689000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59968000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75714000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382052000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-445153000	USD
	us-gaap	Revenues Revenues	44957000	USD
CY2014Q3	us-gaap	Revenues Revenues	14606000	USD
CY2013Q3	us-gaap	Revenues Revenues	16013000	USD
	us-gaap	Revenues Revenues	42301000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	2895000	USD
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5382000	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9617000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10025000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14634000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27679000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122157000	shares
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8587000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8135000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27589000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22991000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11065000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7140000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7400000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8400000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	39940000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-19990000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112554000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124041000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112765000	shares
CY2013Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	3707000	USD
CY2014Q3	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1194000	USD
CY2014Q3	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2179000	USD
CY2013Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	1505000	USD
CY2014Q3	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	5774000	USD
CY2013Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4495000	USD
CY2013Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	3377000	USD
CY2014Q3	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	6840000	USD
CY2014Q3	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	423000	USD
CY2013Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	551000	USD
CY2014Q3	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2202000	USD
CY2013Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3233000	USD
CY2014Q3	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2014Q3	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2014Q3	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	872000	USD
CY2013Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	610000	USD
CY2014Q3	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	800000	USD
	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	1000000	USD
CY2013Q3	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	6500000	USD
	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	7400000	USD
CY2013Q4	halo	Manufacturingcostspreviouslyrecordedforbulkr Hu Ph20 ManufacturingcostspreviouslyrecordedforbulkrHuPH20	1000000	USD
CY2014Q3	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	5840000	USD
CY2013Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	5884000	USD
CY2013Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3522000	USD
CY2014Q3	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3347000	USD
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	125387083	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC

Files In Submission

Name	View Source	Status
0001159036-14-000093-index-headers.html	Edgar Link	pending
0001159036-14-000093-index.html	Edgar Link	pending
0001159036-14-000093.txt	Edgar Link	pending
0001159036-14-000093-xbrl.zip	Edgar Link	pending
ex311q32014.htm	Edgar Link	pending
ex312q32014.htm	Edgar Link	pending
ex32q32014.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
halo-20140930.xml	Edgar Link	completed
halo-20140930.xsd	Edgar Link	pending
halo-20140930_cal.xml	Edgar Link	unprocessable
halo-20140930_def.xml	Edgar Link	unprocessable
halo-20140930_lab.xml	Edgar Link	unprocessable
halo-20140930_pre.xml	Edgar Link	unprocessable
halo3q2014-10q.htm	Edgar Link	pending
pipelineslide30sept2014a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q4 Form 10-Q Financial Statement

#000115903614000093 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q4 Form 10-Q Financial Statement

#000115903614000093 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo